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Abstract 
Background: Gestational diabetes mellitus (GDM) is a significant risk factor for cardiovascular disease (CVD) in later 
life, but the mechanism remains unclear. Adipokine imbalance in the presence of metabolic dysfunction may be a 
key event in promoting CVD. The aim of the study was to examine the relationships between GDM, cardiovascular 
risk, and plasma adiponectin, leptin and the leptin/adiponectin (L/A) ratio in pregnancy and at 5 years after the index 
pregnancy.
Methods: This population-based prospective cohort included 300 women who had an oral glucose tolerance test 
(OGTT) during pregnancy. Five years later, the OGTT was repeated along with dual-energy X-ray absorptiometry, lipid 
analysis, and pulse wave velocity analysis. Fasting adiponectin and leptin levels were measured four times during 
pregnancy and at follow-up.
Results: We found the L/A ratio higher in GDM women both during pregnancy and follow-up compared to non-
GDM women. A high L/A ratio during pregnancy was associated with CV risk based on lipid ratios at follow-up, espe-
cially the TG/HDL-C ratio. Further, interaction analysis indicated that an increase in the L/A ratio of 1 unit was associ-
ated with a higher CV risk in GDM compared to normal pregnancy. Finally, low adiponectin levels independently 
predicted increased lipid ratios at follow-up.
Conclusions: Taken together, our findings suggest that high L/A ratio in pregnancy and in particularly in those with 
GDM are associated with an unfavorable CVD risk profile during follow-up. Future studies should investigate if a dys-
regulated leptin and adiponectin profile during pregnancy is associated with atherosclerotic disease during long-term 
follow-up.
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Background
Adiponectin and leptin are two adipocytokines or adi-
pokines that have been studied extensively due to their 
association with insulin resistance, obesity and cardio-
vascular (CV) risk. Secretion of leptin influence body 
weight, positively associated with percentage body fat, 
suggesting that leptin levels is mediating adiposity signals 
to the brain [1]. Excessive production of leptin is a conse-
quence of resistance to its effect on target organs [2], and 
increased levels are associated with high BMI and insulin 
resistance in type 2 diabetes patients (T2DM) [3]. In con-
trast to leptin, adiponectin has antidiabetic properties, 
and these hormones have also opposing effects on sub-
clinical inflammation. Whereas leptin up-regulates TNF 
and interleukin (IL)-6, adiponectin down-regulates these 
and several other inflammatory mediators [4].
The possibility that leptin and adiponectin may also 
be relevant to vascular disease has been suggested by 
experimental studies showing that leptin promotes 
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atherosclerosis and thrombosis in apolipoprotein E 
(ApoE)-deficient mice [5], whereas adiponectin has been 
shown to attenuate atherosclerosis in mice prone to 
develop atherosclerosis [6]. Furthermore, numerous clin-
ical studies implicate dysregulated leptin and adiponectin 
levels in the progression of T2DM, coronary artery dis-
ease and hypertension [7, 8]. Also, in individuals with-
out manifest CV disease (CVD), high circulating leptin 
and low adiponectin levels are associated with multiple 
CVD risk including lipid dysregulation [1]. Dyslipidemia 
is a major risk factor for CVD and lipid ratios have been 
shown to predict CVD risk better than the individual 
lipids used independently [9].
Due to the opposite metabolic effects of leptin and 
adiponectin, the leptin/adiponectin ratio (L/A ratio) has 
been proposed as a useful marker for metabolic disease 
[10, 11] and may be more strongly associated with T2DM 
risk and first CV event than leptin and adiponectin alone 
[12, 13]. A normal pregnancy results in increased insulin 
resistance. Adiponectin decreases from mid pregnancy 
[14] and leptin increases throughout pregnancy [15]. 
Although not consistently demonstrated, GDM women 
have lower adiponectin and higher leptin levels com-
pared to non-GDM women [16, 17] and the L/A ratio has 
been associated with insulin resistance (HOMA-IR) dur-
ing pregnancy [18].
Leptin, adiponectin and the L/A ratio levels have not 
been prospectively evaluated during pregnancy and 
related to future maternal CVD risk. GDM women are 
more prone to develop CVD later in life and our over-
arching hypothesis is that this enhanced risk may start 
to develop or accelerate during pregnancy. We measured 
circulating leptin and adiponectin in 300 women from a 
prospective cohort study at multiple times during preg-
nancy and at 5-year follow-up. We hypothesized that the 
L/A ratio during pregnancy and at follow-up is associated 




The STORK study was a prospective cohort study with 
a longitudinal design in which 1031 low-risk women of 
Scandinavian heritage who gave birth at Oslo Univer-
sity Hospital Rikshospitalet between 2002 and 2008 
were followed throughout their pregnancy as previously 
described [19]. Exclusion criteria included multiple preg-
nancy, known pre-gestational diabetes, severe chronic 
medical conditions (such as lung, cardiac, gastrointes-
tinal or renal diseases), and pregnancies complicated 
by major fetal malformations. Briefly, each pregnant 
woman had four antenatal visits at gestational age (GA) 
weeks 14–16, 22–24, 30–32, and 36–38. Clinical data and 
blood samples were collected at each visit, processed, and 
stored at −80  °C until further analysis. A 75 g oral glu-
cose tolerance test (OGTT) was performed on all women 
at antenatal GA visit 14–16 and 30–32 weeks.
The current study is a 5-year follow-up after the index 
pregnancy [20]. A total of 1031 participants from the 
original STORK cohort were invited to participate. Exclu-
sion criteria included pregnancy at the time of invita-
tion and/or delivery within the past year. Three hundred 
women agreed to participate. At the time of the 5-year 
follow-up visit, a fasting blood draw was performed to 
measure lipid profiles and a 75 g OGTT was conducted. 
For the purposes of this analysis, the term primiparous 
is used to identify women delivering their first child in 
the index pregnancy (nulliparous) or with only one prior 
delivery at 5-year follow-up. Women with preeclamp-
sia, preterm birth and hypertension without GDM were 
excluded in this particular study.
Measurements of glycemic and lipid parameters
All 75  g OGTTs were performed in the morning after 
an overnight fast. Venous EDTA blood was analyzed 
at point of care using an Accu-Check Sensor glucom-
eter (Roche Diagnostics GmbH, Mannheim, Germany). 
Additional venous blood samples were allowed to clot 
for 30  min and the serum separated by centrifugation 
for 10  min at 3000g and stored at −80  °C. Glucose lev-
els were also measured from frozen serum samples col-
lected at 30–32  weeks using the hexokinase method 
(Hitachi Modular P800, Roche Diagnostics, Mannheim, 
Germany) at an accredited clinical chemistry laboratory 
at Oslo University Hospital Rikshospitalet, as previously 
reported [20]. For the 5-year follow-up study, we used 
the glucose data from the Accu-check Sensor glucom-
eter (Roche Diagnostics, Mannheim, Germany). Insulin 
levels in the stored samples were assayed in duplicate 
by RIA (Diagnostic Products Corporation, Los Angeles, 
CA, USA), as previously reported [20]. Levels of apolipo-
protein A (apoA), apoB, HDL-C, low density lipoprotein 
cholesterol (LDL-C) (direct measurements), and triglyc-
erides (TG) were measured from frozen serum samples 
at follow-up at the clinical chemistry laboratory at Oslo 
University Hospital Rikshospitalet. The ratios of TG/
HDL-C, LDL/HDL-C and apoB/apoA are known risk 
factors for CVD [9, 21, 22], and were calculated based 
on the above measurement. For leptin and adiponec-
tin analysis, we used fasting plasma from venous EDTA 
blood sampled on ice, centrifuged for 25  min at 3000g 
at 4  °C, separated, and stored at −80  °C until analyzed. 
Total adiponectin and leptin were measured in duplicate 
using a commercially available enzyme-linked immuno-
sorbent assay (ELISA; R & D Systems, Minneapolis, MN, 
USA) in a 384 format using the combination of a SELMA 
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(Jena, Germany) pipetting robot and a BioTek (Winooski, 
VT, USA) dispenser/washer (EL406). Absorption was 
read at 450 nm with wavelength correction set to 540 nm 
using an ELISA plate reader (Synergy H1 Hybrid, Biotek, 
Vinooski, VT, USA).
Diagnosis of GDM
GDM was diagnosed on a 75  g OGTT using the WHO 
criteria from 1999: 2 h plasma glucose ≥7.8 mmol/L [23]. 
Estimation of insulin sensitivity was measured on the 
same samples collected at the time of OGTT using the 
Matsuda index (i.e., 10,000/square root of [fasting glu-
cose (mmol/L) × fasting insulin (mU/L)] × [mean glu-
cose (mmol/L) × mean insulin (mU/L)]) during OGTT. 
This index is a measure of whole body insulin sensitivity 
that has been validated against the euglycemic-hyper-
insulinemic clamp [24]. Estimation of β-cell function 
was assessed with the insulin secretion-sensitivity index 
(ISSI-2) (area under the curve (AUC) insulin (mU/L)0–
120/glucose (mmol/L)0–120 × Matsuda), which has been 
validated against the disposition index from the intrave-
nous GTT [25]. Estimation of homeostasis model assess-
ment: insulin resistance (HOMA–IR) was calculated as 
fasting insulin (mU/L) ×  fasting glucose (mmol/L)/22.5, 
as previously described by Matthews et al. [26]. Although 
the insulin sensitivity has been validated against the eug-
lycemic-hyperinsulinemic clamp and the β-cell function 
against the disposition index from the intravenous GTT, 
these are estimates, and therefore a limitation of the 
study.
Measurements of arterial stiffness
Aortic stiffness was assessed by means of PWV meas-
urements using SphygmoCor (Atcor Medical, Sydney, 
Australia), a non-invasive technique with direct-contact 
pulse sensors, and the method and results have previ-
ously been published [27].
Measurements of body fat composition
Total body composition was determined by dual-energy 
X-ray absorptiometry (DXA; GE Lunar Prodigy Densi-
tometer, software version 12.10, GE Medical Systems, 
Lunar Corp., Madison, WI, USA) and analyzed using 
enCORE software (version 14.10; GE Medical Systems), 
as previously described [20].
Statistical analysis
Statistical analyses were conducted using SPSS for Win-
dows, version 21.0 (Chicago, IL, USA). Data are expressed 
as mean  ±  SD when normally distributed and median 
(25th, 75th percentile) when skewed. Comparison 
between women with and without a history of GDM was 
performed using t test or Mann–Whitney U depending 
on distribution, and Chi square test for categorical vari-
ables. Several multiple regression models were used in 
the study. We first performed a stepwise linear regression 
to determine the most important and consistent predic-
tors of the L/A ratio at multiple times during pregnancy 
(listed in Table  2). These were used as adjustment vari-
ables in subsequent forced logistic regression analysis 
when calculating odds ratios for leptin, adiponectin and 
the L/A ratio according to established cut-offs for the 
apoB/apoA, LDL/HDL-C ratio and TG/HDL-C ratio. We 
also performed linear regression to identify the strong-
est predictors at 5 years follow-up of the different lipid-
ratios at 5 years follow-up using a comprehensive list of 
metabolic factors (listed in Table 3). Univariate and step-
wise (probability of F to-enter 0.1-remove 0.15) linear 
regression analyses were carried out on log transformed 
variables (if skewed) and results given as standardized 
regression coefficients. Only variables below p < 0.2 were 
included in the stepwise multivariable models (the varia-
bles marked in bold). For determining the number of pre-
dictors we used the rule of thumb that we could include 
n ≥ 50 + 8 * number of predictors [28]. With, n = 272 we 
could include 25–30 independent predictors. Post-hoc 
power calculations revealed that the multiple regression 
models had power ~1.00. Two-tailed p values <0.05 were 
considered significant.
Results
Table  1 shows the characteristics of the study popu-
lation at the time of the 5-year follow-up visit strati-
fied into those women who did and did not have GDM 
in the index pregnancy using WHO criteria (based on 
the OGTTs), which we have recently demonstrated are 
at particular CV risk (compared to IADPSG criteria) 
[27]. Women with GDM based on the WHO criteria 
had a higher BMI at week 14–16 [26.0 (22.6–28.7) kg/
m2 vs. 23.6 (21.5–25.6) kg/m2] and at week 30–32 [27.8 
(25.7–31.2) kg/m2 vs. 26.5 (24.0–28.6) kg/m2, p = 0.011 
and p = 0.029 respectively], and as evident from Table 1, 
at follow-up after 5  years compared to their non-GDM 
counterparts and were more frequently smokers at 
follow-up. Further, the GDM women had a higher esti-
mated insulin resistance, unfavorable lipid ratios (i.e., 
higher TG/HDL-C, LDL/HDL-C and apoB/apoA), lower 
estimated insulin sensitivity and lower estimated β-cell 
function at the 5-year follow-up visit.
Women with GDM have higher plasma leptin, leptin/
adiponectin ratio and lower adiponectin in pregnancy 
and at follow‑up compared to non‑GDM women
As shown in Fig.  1a, plasma adiponectin decreased 
from 14–16 weeks to 30–32 weeks in non-GDM women 
and then increased to 5  years follow-up. In contrast, a 
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marked decrease from 14–16 weeks to 22–24 weeks was 
observed in women with GDM, reaching levels signifi-
cantly lower than in non-GDM women, and importantly, 
adiponectin remained low throughout the observation 
period showing significantly lower levels compared to 
non-GDM women after 5  years. Leptin levels increased 
during pregnancy from 14–16  weeks to 30–32  weeks 
with a marked decrease during follow-up in both GDM 
and non-GDM women, but notably, leptin levels were 
significantly higher at week 14–16 and 5 year follow-up 
in the GDM group (Fig. 1b). A similar temporal pattern 
as for leptin was found for the L/A ratio although women 
with GDM had significantly higher ratios at all time-
points (except 36–38 weeks), Fig. 1c.
Associations between L/A ratio and clinical characteristics 
in pregnancy
Our hypothesis was that the L/A ratio were associated 
with CV risk and we therefore evaluated the associa-
tion between this ratio and clinical variables at each visit 
(Table  2). Briefly, BMI, systolic BP, CRP and estimated 
insulin resistance was consistently positively-, while esti-
mated insulin sensitivity and β-cell function were con-
sistently negatively, associated with the L/A ratio at each 
visit in univariate analysis. Stepwise multivariable linear 
regression revealed that BMI and estimated insulin sen-
sitivity were the strongest predictors of the L/A ratio at 
most visits (Table 2).
Leptin/adiponectin ratio in pregnancy as CV risk marker
We have previously reported that GDM women in our 
study have enhanced CV risk based on elevated arterial 
stiffness and lipid ratios [27]. We next assessed if the L/A 
ratio at different time points in pregnancy could predict 
CV risk at 5 years follow-up based on TG/HDL-C ratio, 
apoB/apoA ratio and LDL/HDL-C ratio. ROC analy-
sis (Additional file  1: Table  S1) demonstrated that adi-
ponectin, leptin and the L/A ratio significantly predicted 
Table 1 Characteristics of  the study population at  5  year 
follow-up
Data given as mean ± SD when normal distributed and median (25th, 75th) 
when skewed distributed. Preterm delivery (n = 12), hypertension (n = 7) and 




N = 241 31
Follow-up time 4.8 (4.4, 5.4) 5.0 (4.5, 5.4)
Age (years) 37.5 ± 3.8 38.6 ± 3.8
Height (cm) 169 ± 6 168 ± 5
BMI (kg/m2) 22.8 (20.9, 25.2) 24.1 (21.7, 28.1)*
Primipara n (%) 217 (90.0) 25 (80.6)
Family history heart disease n 137 (57.3) 22 (75.9)
Family history diabetes n (%) 74 (30.7) 13 (41.9)
Currently smoking n (%) 38 (20.4) 9 (39.1)*
Previous smoker n (%) 55 (27.1) 8 (36.4)
Systolic blood pressure (mmHg) 110 (100, 120) 110 (100, 130)
Diastolic blood pressure (mmHg) 70 (60, 74) 70 (65, 80)
Insulin sensitivity 275 (196, 377) 210 (126, 304)**
Insulin resistance 0.67 (0.44, 0.97) 0.96 (0.48, 1.33)*
Β-cell function 1049 (816, 1373) 712 (559, 1247)**
TG/HDL-C ratio 0.46 (0.36, 0.63) 0.65 (0.45, 1.03)**
LDL/HDL-C ratio 1.65 (1.25, 2.04) 2.00 (1.62, 2.48)*
ApoB/ApoA ratio 0.44 (0.36, 0.53) 0.53 (0.42, 0.62)*
Fig. 1 Circulating levels of a adiponectin, b leptin, and c L/A ratio in pregnancy and at 5-year follow-up between GDM (WHO) (red line) and non-
GDM (blue line). FU, follow-up. Data is given as mean, 95% CI. *p < 0.05, **p < 0.01 GDM compared with non-GDM group. The p values in each graph 
represents the group effect/interaction term (in italic) from repeated measures ANOVA. Time was significant for all variables (p < 0.001)
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enhanced CV risk based on established cut-offs [9, 21, 
22] for the ratios of TG/HDL-C ratio, apoB/apoA ratio 
and LDL/HDL-C ratio at 5 years follow-up. The L/A ratio 
showed the highest AUCs for all lipid ratios, but the asso-
ciation with the TG/HDL-C ratio was particularly strong 
at all time-points (Fig.  2a). As shown in Fig.  2b and c, 
women with enhanced risk as suggested by increased 
TG/HDL-C (i.e.  ≥1.09) at 5  years follow-up, displayed 
markedly lower adiponectin, and higher leptin and L/A 
ratios, at all time-points during and after pregnancy. 
However, in contrast to leptin, which displayed a similar 
pattern in the TG/HDL-C groups, adiponectin increased 
from week 30–32 to follow-up in women with low TG/
HDL-C, but decreased in women with a high TG/HDL 
ratio (Fig. 2b).
Since BMI and estimated insulin sensitivity were 
strongly correlated with the L/A ratio, we evaluated if 
the association between the L/A ratio in pregnancy and 
enhanced CV risk as determined by a high TG/HDL-C 
ratio was modified by these measures using logis-
tic regression. As shown in Fig.  2d, the OR’s were only 
slightly attenuated, and remained significant at all time-
points after adjusting for BMI and estimated insulin 
sensitivity. A similar pattern, although of more modest 
statistical significance, was observed for the LDL/HDL-C 
and apoB/apoA ratios (Additional file 1: Table S2).
L/A ratio and interaction with GDM on CVD risk
To further evaluate whether the associations between 
the L/A ratio and CV risk measurements were stronger 
in women with previous GDM, we performed an interac-
tion analysis. As shown in Fig. 3a, we found a significant 
interaction between GDM and the L/A ratio at 5-year 
follow-up for the TG/HDL-C ratio, and this interaction 
was also present at all visits during pregnancy. Similar 
interactions between GDM and the L/A ratio were pre-
sent for the LDL/HDL-C and apoB/apoA ratio at 5-year 
follow-up (Fig. 3b, c). Thus, an increase in the L/A ratio 
of 1 unit is associated with a larger increase in CV risk 
in women with previous GDM compared to uncom-
plicated pregnancy suggesting that a high ratio may 
enhance the adverse effects of glucose intolerance on the 
TG/HDL ratio. The change in the L/A ratio from visit 1 
to 4 in pregnancy was associated with the TG/HDL-C 
ratio at follow-up in GDM women (r = 0.49, p = 0.008) 
but no associations was observed in controls (r =  0.01, 
p = 0.90).
Predictors of cardio‑metabolic risk factors 5‑year follow‑up
We finally evaluated the association between adiponec-
tin, leptin, the L/A ratio and lipid ratios as continu-
ous variables at 5-years follow-up in regression models 
with established CVD risk factors. As shown in Table 3, 
despite slightly weaker or similar correlations with 
the lipid ratios as the L/A ratio, adiponectin together 
with estimated insulin sensitivity or insulin resistance, 
remained a predictor in the final model, suggesting 
effects on CV risk independent of associations with glu-
cose metabolism. PWV (reported previously in [27] cor-
related modestly with leptin (r =  0.14, p =  0.022), the 
Table 2 Association between L/A ratio and clinical characteristics throughout pregnancy and at 5 year follow-up





b Previous and current, Linear regression (Beta, p)
c Measures of glucose metabolism not available at indicated time-point
14–16 weeks 22–24 weeksc 30–32 weeks 36–38 weeksc 5 year. follow‑up
Uni Multi Uni Multi Uni Multi Uni Multi Uni Multi
Age −0.02 −0.01 −0.03 −0.13* −0.12* −0.01
BMI 0.70*** 0.53*** 0.68*** 0.50*** 0.61*** 0.38*** 0.61*** 0.50*** 0.73*** 0.56***
Paritya 0.05 0.02 −0.01 −0.08 −0.14** 0.04
Smokingb 0.16* 0.15* 0.09 0.18** 0.01
Systolic BP 0.26*** 0.20** 0.22*** 0.25*** 0.28***
CRP 0.25*** 0.32*** 0.28*** 0.20*** 0.32***
Insulin sensitivity −0.60*** −0.32*** −0.61** −0.35*** −0.61*** −0.24* −0.50*** −0.37*** −0.61*** −0.29***
Insulin resistance 0.56*** 0.53*** 0.59*** 0.28* 0.48*** 0.56***
Β-cell function −0.39*** −0.38*** −0.33*** 0.20** −0.18*** 0.17** −0.45***
R-square 0.56 0.55 0.49
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L/A ratio (r = 0.12, p = 0.041), but not with adiponectin 
(r = −0.03, p = 0.59) and was also a predictor in the final 
model for apoB/apoA ratio. Smoking, systolic BP, CRP 
and GDM were included as predictors in the final model 
when investigating TG/HDL-C ratio.
Discussion
The present study investigated the significance of leptin, 
adiponectin and their ratio in pregnancy and follow-up 
between GDM vs. non-GDM women and associations 
with CV risk as evaluated by unfavorable lipid ratios at 
5  years follow-up. Our main findings were: (1) The L/A 
ratio was higher in GDM women both during pregnancy 
and follow-up compared to non-GDM women (2) a high 
L/A ratio during pregnancy was associated with CV risk 
based on unfavorable lipid ratios at follow-up, especially 
the TG/HDL-C ratio (3) interaction analysis indicated 
that an increase in the L/A ratio of 1 unit was associ-
ated with a higher CV risk in GDM compared to normal 
pregnancy (4) low adiponectin levels independently pre-
dicted unfavorable lipid ratios at follow-up. Our findings 
suggest that high L/A ratio is associated with CV risk in 
women with GDM, potentially also being involved in the 
pathogenesis of CVD in these women.
Fig. 2 a Receiver operating characteristic (ROC) curves for predicting TG/HDL-C ratio at 5 year by adiponectin (blue line), leptin (brown line) and 
L/A ratio (red line) in pregnancy. b Adiponectin c leptin and L/A ratio in all pregnancy and 5 year follow-up divided by high (red line) and low (blue 
line) TG/HDL-C ratio. *p < 0.05, **p < 0. 01, ***p < 0.001. The p value represents the group effect/interaction term (in italic) from repeated measures 
ANOVA. Time was significant for all variables (p < 0.001). d Univariate (red circles) and adjusted (blue circles) models for increased CV risk as reflected 
by the TG/HDL-C ratio by L/A ratio during pregnancy. The adjusted analysis included BMI and estimated insulin sensitivity acquired at the same time 
as the L/A ratio
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Our study demonstrates that circulating adiponec-
tin levels are lower early in pregnancy in women who 
develop GDM supporting a number of studies evaluat-
ing this protein during pregnancy as highlighted in a 
recent meta-analysis [29]. Conversely, increased lep-
tin levels have been reported frequently in GDM [16] 
although this increase was less impressive in our study. 
This could be a power issue, although Retnakaran et  al. 
Fig. 3 Interaction analysis between L/A ratio in pregnancy and 5-year follow-up and a TG/HDL-C ratio in GDM (red circles) and non-GDM (blue 
circles) women. Interaction analysis between L/A ratio at 5-year follow-up and b LDL/HDL-C ratio and c apoB/apoA ratio in GDM and non-GDM 
women. p values indicates interaction analysis
Table 3 Markers of cardio-metabolic risk factors at 5-year follow-up for the whole cohort





b Previous and current, Linear regression (Beta, p)
TG/HDL ratio ApoB/apoA ratio LDL/HDL ratio
Uni Multi Uni Multi Uni Multi
Follow-up 0.01 −0.01 −0.04
Age 0.02 −0.01 0.01
BMI 0.41*** 0.28*** 0.31***
Parity −0.06 −0.09 −0.08
Smoking 0.14* 0.13* 0.07 0.04
Diabetes in family 0.10 0.09 0.07
Heart disease in family 0.03 0.01 0.04
Systolic BP 0.27*** 0.22** 0.10 0.11
Diastolic BP 0.13* 0.02 0.01
CRP 0.30** 0.10 0.13 0.15*
Insulin sensitivity −0.50*** −0.31*** −0.33*** −0.25*** −0.39***
Insulin resistance 0.44*** 0.31*** 0.36*** 0.32***
Β-cell function −0.40*** −0.29*** −0.32***
PWV 0.24*** 0.15* 0.10 0.15*
Visceral fat 0.41*** 0.30*** 0.32***
Leptin 0.32*** 0.16** 0.21***
Adiponectin −0.37*** −0.18** −0.26*** −0.17** −0.27*** 0.17**
L/A ratio 0.43*** 0.25 *** 0.31***
GDM WHO 0.27** 0.16** 0.18** 0.18**
R square 0.35 0.15 0.17
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found no difference in 2nd trimester leptin levels when 
evaluating the impact of glucose tolerance in pregnancy 
(n  =  487) including 137 GDM women [17]. Indeed, 
experimental studies indicate that the effects of leptin on 
glucose homeostasis are suppressed during pregnancy 
[30]. Furthermore, both diet and low birthweight may 
have an impact on leptin levels, irrespective of body mass 
[31, 32]. A low birth weight was associated with a higher 
prevalence of diabetes and obesity, higher leptin levels 
and leptin to fat mass ratio possibly related to nutrition 
or the development of leptin resistance and/or higher 
leptin production by body fat unit [32]. Fewer studies 
have evaluated the longitudinal trajectory of these pro-
teins during pregnancy and beyond. In contrast to nor-
mal pregnancy, where the lowest adiponectin levels were 
observed at 30–32  weeks and then increased steadily, 
adiponectin floored at 22–24 weeks in GDM women and 
remained low also at the 5 year follow-up. Thus, our data 
extend previous findings by showing that persistently low 
adiponectin levels, also during follow-up after pregnancy 
may represent a risk factor for future development of 
metabolic and CV disease in GDM women.
We and others have shown that women with a history 
of GDM display an unfavorable lipid profile [27, 33, 34] 
with enhanced ratios such as TG/HDL-C as a marker of 
cardiometabolic risk [27]. While leptin and adiponec-
tin, and their association with measures of adiposity 
and glucose metabolism are well established in GDM, 
their associations with surrogate markers of CV risk 
in these women, or during normal pregnancy, are less 
documented. Men with a high ratio of adiponectin/lep-
tin (opposite of L/A ratio) had lower TG and TG/HDL-C 
ratios [35]. It has been suggested that the L/A ratio may 
serve as a potential atherogenic index in obese T2DM 
patients [11] and in metabolic syndrome [36].  A close 
correlation with carotid intima-media thickness, a sur-
rogate marker of atherosclerosis, has been documented 
in T2DM [10] and in healthy subjects [37]. We have pre-
viously demonstrated a higher arterial stiffness as meas-
ured by PWV at 5 years follow-up in these GDM women 
[27], but detected only a modest association between 
leptin and the L/A ratio and PWV in the present study. 
Thus, our findings are limited by the relatively young age 
of the women and lack of manifest CVD during follow-
up. Nonetheless, our finding that the L/A ratio through-
out pregnancy consistently predicted CV risk at 5 years 
follow-up, better than adiponectin or leptin alone, and 
with good accuracy based on the apoB/apoA ratio, LDL/
HDL-C ratios, and in particular the TG/HDL-C ratio, 
suggest that a dysregulated leptin and adiponectin pro-
file should be further evaluated in relation to CVD during 
long-term follow-up after pregnancy.
Previous studies have demonstrated an association 
between the L/A ratio, BMI and insulin resistance in 
obese patients, patients with metabolic syndrome and 
in non-diabetic adults [38, 39]. Similar associations were 
also observed in pregnant women [18] and our finding 
that BMI and estimated insulin sensitivity were major 
predictors of the L/A ratio throughout pregnancy sup-
port these findings. Importantly, however, the associa-
tion between the L/A ratio and an elevated TG/HDL-C 
ratio at 5 years persisted following adjustment for these 
factors, with similar, albeit weaker, associations with the 
other lipid ratios especially towards the end of preg-
nancy. In addition to contributing to enhanced CV risk 
through metabolic pathways related to adiposity and 
insulin resistance, adiponectin and/or leptin could there-
fore have independent effects as well [11]. Our finding 
that adiponectin, but not the L/A ratio, was a predic-
tor of the TG/HDL-C ratio at 5  years follow-up, may 
suggest that while the L/A ratio represents a stronger 
risk marker, this risk is at least partly mediated by adi-
ponectin. Indeed, adiponectin may directly affect the 
metabolism of HDL and TG rich lipoproteins [40, 41]. 
Furthermore, adiponectin attenuates the inflammatory 
response to multiple stimuli by modulating signaling 
pathways in a variety of cell types [42]. Both adiponec-
tin and leptin have been shown to affect atherosclerotic 
progression [43]. While adiponectin may be protective 
in atherosclerosis by diminishing endothelial injury, 
which is the first step in atheroma formation [44], lep-
tin increase the secretion of inflammatory markers [45]. 
Adiponectin may also inhibit endothelial inflammation 
and correlates negatively with vascular inflammation 
markers such as VCAM-1 and ICAM-I [46]. Conversely, 
leptin increases these markers, which favors monocyte 
attraction and migration through the endothelial wall 
[47]. Adiponectin may also modulate macrophages to 
an anti-inflammatory phenotype and inhibit foam cell 
transformation [48]. Thus, having a dysregulated adi-
ponectin and leptin profile, as showed in GDM women, 
may potentially have deleterious effects on atherosclero-
sis development.
In addition to be a risk marker for CVD through its 
effect on L/A ratio, adiponectin could also be involved 
in the pathogenesis of CVD following GDM. Finally, our 
interaction analysis showing that a change in the L/A 
ratio throughout pregnancy and at follow-up was asso-
ciated with a larger increase in the TG/HDL-C, as well 
as the LDL/HDL-C and apoB/apoA ratio, supports that 
the L/A ratio may be of particular relevance in GDM and 
enhance the adverse effects of glucose intolerance on CV 
risk. Indeed, while change in the L/A ratio from early to 
late pregnancy was not associated with any of the lipid 
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ratios in normal pregnancy, this change correlated well 
with the TG/HDL-C ratio in GDM women.
Conclusions
Taken together, our findings suggest that high L/A ratio 
in pregnancy and in particularly in those with GDM are 
associated with an unfavorable CV risk profile during 
follow-up. Future studies should investigate if a dysregu-
lated leptin and adiponectin profile during pregnancy is 
associated with atherosclerotic disease during long-term 
follow-up.
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